Literature DB >> 7826819

Clinical pharmacology, physiology and pathophysiology of superficial veins--1.

W H Aellig1.   

Abstract

1. Venous resistance contributes very little to total peripheral resistance; more than half of the total blood volume, however, is contained in the extrathoracic veins. Owing to marked differences between venous and arterial anatomy and physiology, studies on veins and arteries usually require different methodological approaches. Whereas for arteries the most relevant parameters are resistance, pressure and flow, for veins volume and compliance are most important. For studies of general aspects of the peripheral circulatory system, venous occlusion plethysmography is probably the most useful method. The determination of both the rate of rise in limb volume and the total volume rise after inflating a proximally applied occlusion cuff to a subdiastolic pressure permits the concomitant estimation of both arterial flow and venous compliance. 2. Studies of direct pharmacological or physiological effects on veins, interactions of various pharmacological or physiological stimuli, or pathophysiological changes in venous responsiveness have been facilitated by the development of investigational techniques relying on direct measurements of the compliance of single human veins in vivo. One of these, relying on the use of a linear variable differential transformer (LVDT) for determining changes in the compliance of superficial veins at a standardized congestion pressure, has been found very suitable for the practical application in both patients and healthy subjects. 3. Physiological studies were carried out on the effect of age, exercise, temperature, and the menstrual cycle on venous compliance and venous responsiveness to various stimuli. In addition, interindividual variability in venous responsiveness in monozygotic and dizygotic twins and in unrelated subjects was investigated, and studies on the function of the endothelium were carried out in man in vivo. 4. Pathophysiological studies using this technique were reported from patients with hypertension, orthostatic hypotension, myocardial infarction, varicosis, cystic fibrosis, asthma, diabetes, systemic sclerosis, and cluster headache. 5. Clinical pharmacological studies represent a most important field for the use of this method. Studies were carried out on the effects of a large number of constrictor and dilator agents, and also on drug interactions on human veins in vivo. Venoconstriction was observed after local administration of alpha-adrenoceptor and 5-HT-receptor agonists, ergot derivatives, angiotensinogen, angiotensin I and II, and several prostaglandins. 6. Owing to the low venous tone present under effects can usually be quantified only on veins e.g. noradrenaline or 5-hydroxytryptamine. Under these conditions dilatation was observed after the administration of beta-adrenoceptor agonists, cholinergic (muscarinic) agonists, nitrates, calcium antagonists, bradykinin, substance P and several prostaglandins.

Entities:  

Mesh:

Year:  1994        PMID: 7826819      PMCID: PMC1364788          DOI: 10.1111/j.1365-2125.1994.tb04341.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Assessment of venous capacitance. Radionuclide plethysmography: methodology and research applications.

Authors:  Matthias Schmitt; Daniel J Blackman; Gordon W Middleton; John R Cockcroft; Michael P Frenneaux
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

2.  Effects of different congestion pressures on the diameter of the dorsal hand vein and on its apparent sensitivity to noradrenaline.

Authors:  A H Abdelmawla; R W Langley; E Szabadi; C M Bradshaw
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

3.  Long-term effects of nasal continuous positive airway pressure on vasodilatory endothelial function in obstructive sleep apnea syndrome.

Authors:  Hans-W Duchna; Maritta Orth; Gerhard Schultze-Werninghaus; Christian Guilleminault; Riccardo A Stoohs
Journal:  Sleep Breath       Date:  2005-09       Impact factor: 2.816

4.  Independent regulation of α1 and α2 adrenergic receptor-mediated vasoconstriction in vivo.

Authors:  Mordechai Muszkat; Daniel Kurnik; Gbenga G Sofowora; Alastair J J Wood; C Michael Stein
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

5.  Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man.

Authors:  A H Abdelmawla; R W Langley; E Szabadi; C M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

6.  Comparison of the effects of desipramine on noradrenaline- and methoxamine-evoked venoconstriction in man.

Authors:  A H Abdelmawla; R W Langley; E Szabadi; C M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

7.  The effects of age on human venous responsiveness to neuropeptide Y.

Authors:  M L Lambert; I D Callow; Q P Feng; J M Arnold
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

8.  Desensitization of vascular response in vivo: contribution of genetic variation in the [alpha]2B-adrenergic receptor subtype.

Authors:  Mordechai Muszkat; Daniel Kurnik; Gbenga G Sofowora; Joseph Solus; Hong-Guang Xie; Paul A Harris; Scott M Williams; Alastair J J Wood; C Michael Stein
Journal:  J Hypertens       Date:  2010-02       Impact factor: 4.844

9.  Autonomic dysreflexia in tetraplegic patients: evidence for alpha-adrenoceptor hyper-responsiveness.

Authors:  J M Arnold; Q P Feng; G A Delaney; R W Teasell
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

10.  Genetic variation within adrenergic pathways determines in vivo effects of presynaptic stimulation in humans.

Authors:  Maple M Fung; Carie Nguyen; Parag Mehtani; Rany M Salem; Brandon Perez; Brenda Thomas; Madhusudan Das; Nicholas J Schork; Sushil K Mahata; Michael G Ziegler; Daniel T O'Connor
Journal:  Circulation       Date:  2008-01-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.